Short description
Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.
Description
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Boston, Massachusetts, United States, North America
Founded on
January 1, 2020
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Absolutely Noaccess
Sign in for full access
Founders
Michael Ehlers